/Investor DB

53 Stations — 2025 Investments

3 investments dated 2025 · listed companies and verified rows first · show all

Antaresantaresindustries.comin𝕏Oct 2025

Antares Industries develops nuclear reactor technology, with teams spanning nuclear, reactor hardware, and mission engineering as well as manufacturing and regulatory operations.

Advanced ManufacturingCleantechDeep TechDefense TechEnergyParker, US

Jordan Bramble(CEO & Co-Founder)inJulia DeWahl(Founder)inRian Bahran(Chief Nuclear Officer)inMark Massie(Chief Engineer)inDONALD G MACK(Executive Officer, Director)

BoardJack Altman(Director)

Co-investorsAtacama VenturesBalerion Space VenturesBoxGroupCaffeinated CapitalHeartfelt CapitalHumba Ventures+21 more

Ketryxketryx.cominSep 2025 · $39M

Ketryx builds a software platform for developing and validating regulated AI and safety-critical software, helping MedTech, biotech, and life sciences companies meet standards such as ISO 13485, IEC 62304, and ISO 14971.

AI & Machine LearningDigital HealthEnterprise SoftwareMedical DevicesSaaSSomerville, US

Erez Kaminsky(President)Erez Kaminski(CEO & Founder)inJan Pöschko(CTO & Founder)inMary Brook Delano(Chief Business Officer)inBrian Katzman(Chief Marketing Officer)in

BoardHabib Haddad(Director)in

Co-investorsLightspeed Venture PartnersThe E14 FundTRANSFORMATION CAPITALUbiquity Ventures

Labvivalabviva.cominJan 2025 · $25M

Labviva is an AI-native procurement platform that unifies the life sciences supply chain, helping research organizations optimize procurement processes and reduce costs.

AI & Machine LearningBiotechEnterprise SoftwareSaaSCambridge, US

Siamak Baharloo(Executive Officer, Director)inCarlo(GM of Europe)inNick Premnath(SVP of Commercial Strategy)inAaron Miramontes(Executive Officer)Nicholas Rioux(Executive Officer, Director)in

BoardSarah Fay(Director)in

Co-investorsBIOSPRING PARTNERSGlasswing VenturesVillage GlobalB Capital GroupB4 CapitalMassVentures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.